To continue reading this content, please enable JavaScript in your browser settings and refresh this page. The French drug maker says it could boost its price ...
SAN FRANCISCO--(BUSINESS WIRE)--Medivation, Inc. (NASDAQ:MDVN) today reiterated its rejection of Sanofi's substantially inadequate proposal to acquire the Company for $52.50 per share in cash, ...
Medivation reported positive Phase 3 test results for its MDV3100 prostate-cancer drug. MDVN more than doubled before the bell. Wireless Lifts Qualcomm Qualcomm reported fourth-quarter earnings of ...
What: Following reports that companies eager to expand their presence in oncology could be knocking on the company's door, shares of Medivation, skyrocketed 25.1% last month, according to data from ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. More-detailed information about a late-stage prostate ...
Collapsing oil prices are one thing, but oil refineries must now contend with the soaring cost of renewable energy credits. By Amie Tsang A heated auction and back-of-the-envelope math hint that the ...
Collapsing oil prices are one thing, but oil refineries must now contend with the soaring cost of renewable energy credits. By Amie Tsang A heated auction and back-of-the-envelope math hint that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results